Monopar Therapeutics (MNPR) IPO Opens Modestly Higher

Today's IPO for Monopar Therapeutics Inc. (MNPR) opened for trading at $8.35 after pricing 1,111,112 shares of its common stock at $8.00 per share.

In addition, the underwriters have been granted a 30-day option to purchase up to an additional 166,666 shares.

JonesTrading Institutional Services LLC acted as Lead Bookrunning Manager and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as Co-Manager for the offering.

Monopar Therapeutics is a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101.

You May Also Be Interested In